尼古丁胺调节肠道微生物的代谢潜力,并加速在轻度至中度的COVID-19中恢复
Stefan Schreiber1,2, Georg H Waetzig3,4, Víctor A López-Agudelo3
1Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany. s.schreiber@mucosa.de.
Nature metabolism
|May 12, 2025
概括
尼古丁胺补充剂改善了COVID-19患者的身体恢复,并减少了长期COVID症状. 这种干预也积极调节了肠道微生物组,为COVID-19恢复提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 微生物学 微生物学
- 临床医学 临床医学
背景情况:
- COVID-19与细胞NAD+耗尽,改变酸盐代谢和肠道失调有关.
- 这些代谢和微生物的变化与疾病的严重程度和不良结果相关.
研究的目的:
- 调查尼古丁胺补充剂在缓解COVID-19症状中的有效性.
- 评估尼古丁胺对三甲代谢,肠道微生物群和长期恢复的影响.
主要方法:
- 这是一项为期4周的双盲,随机,安慰剂对照试验,涉及900名COVID-19症状的门诊患者.
- 参与者接受了一种新的尼古丁胺胺配方 (1000毫克) 或安慰剂.
- 评估了临床结果,身体表现,恢复正常活动以及肠道基因组特征.
主要成果:
- 尼古丁胺在第二周显著加快了表现下降的恢复 (57.6%对42.6%,P=0.004) 和恢复正常活动 (P=0.009).
- 与调节COVID-19相关的便微生物组变化相关的临床改善.
- 与安慰剂反应者相比,尼古丁胺胺反应的患者在6个月后报告了较少的COVID后症状 (P=0.010).
结论:
- 尼古丁胺补充剂为COVID-19患者更快地恢复身体提供了一种安全有效的策略.
- 该干预措施对肠道微生物组产生了积极的影响,这表明它在减轻COVID-19相关的失生症方面发挥了作用.
- 尼古丁胺可以通过代谢和微生物组调节来减少长期COVID症状的发生率.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
786
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
397
相关概念视频
01:40Overview of Metabolism
29.2K
Living cells constantly carry out various chemical reactions which are necessary for their proper functioning. These reactions are interlinked to one another via multiple pathways. The collection of these chemical reactions is known as metabolism.
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
29.2K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.2K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.2K